

Cite this: *Chem. Sci.*, 2022, 13, 5562

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Enantioselective construction of *cis*-hydroindole scaffolds via an asymmetric inverse-electron-demand Diels–Alder reaction: application to the formal total synthesis of (+)-minovincine†

Fangqing Zhang,<sup>ab</sup> Bing-Tao Ren,<sup>b</sup> Yuqiao Zhou,<sup>id c</sup> Yangbin Liu<sup>\*bc</sup> and Xiaoming Feng<sup>id \*bc</sup>

*cis*-Hydroindole scaffolds widely exist in a large number of natural products, pharmaceuticals, and organocatalysts. Therefore, the development of efficient and enantioselective methods for the construction of *cis*-hydroindoles is of great interest and importance. Herein, a novel approach for the enantioselective synthesis of *cis*-hydroindole scaffolds has been realized through a chiral *N,N'*-dioxide/Mg(OTf)<sub>2</sub> complex catalyzed asymmetric inverse-electron-demand Diels–Alder (IEDDA) reaction of 2-pyrones and cyclic enamines. A series of substituted *cis*-hydroindole derivatives bearing multiple contiguous stereocenters and functional groups were obtained in good to excellent yields and enantioselectivities (up to 99% yield, and 95% ee) under mild reaction conditions. Moreover, the enantioselective formal total synthesis of (+)-minovincine was concisely furnished with high efficiency and stereoselectivity to demonstrate the synthetic potential of this method.

Received 13th March 2022

Accepted 14th April 2022


DOI: 10.1039/d2sc01458k

rsc.li/chemical-science


## Introduction

Chiral *cis*-hydroindole is a privileged scaffold present in numerous biologically active natural products<sup>1–8</sup> such as minovincine, kopsinine, vindolinine, and aeruginosin 298-A, pharmaceutical products<sup>9</sup> such as the antihypertensive drug perindopril, and proline analogue organocatalysts<sup>10,11</sup> (Scheme 1a). Complex molecular architectures and fascinating biological properties have long motivated the development of synthetic methods towards enantioselective construction of chiral *cis*-hydroindoles.<sup>12–15</sup> In this context, most strategies for the stereoselective construction of *cis*-hydroindoles are primarily based on using optically active starting materials.<sup>12,13a,b,13d</sup> In contrast, catalytic asymmetric reactions that rely on the use of readily accessible prochiral substrates to achieve enantioenriched *cis*-hydroindoles are still relatively rare. Mechanistically, these synthetic tactics are largely carried out by asymmetric (aza-) Michael additions.<sup>13c,14,15</sup> Therefore, the development of a general and novel strategy for concise and efficient


### a) *Cis*-hydroindole scaffold in natural products, pharmaceuticals and organocatalysts




### b) Retrosynthetic analysis of *cis*-hydroindole scaffold via IEDDA



### c) Diastereoselective IEDDA reaction of 2-pyrones and chiral cyclic enamines (Jiang)



### d) This work: catalytic asymmetric IEDDA reaction of 2-pyrones and cyclic enamines



Scheme 1 Enantioselective synthesis of the *cis*-hydroindole scaffold.

<sup>a</sup>State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, 518055, China

<sup>b</sup>Shenzhen Bay Laboratory, Shenzhen, 518055, China. E-mail: liuyb@szbl.ac.cn

<sup>c</sup>Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, 610064, China. E-mail: xmfeng@scu.edu.cn

† Electronic supplementary information (ESI) available. CCDC 2158164. For ESI and crystallographic data in CIF or other electronic format see <https://doi.org/10.1039/d2sc01458k>


manipulation of densely functionalized *cis*-hydroindole derivatives with multiple stereocenters remains a significant challenge.

As one of the most important and fundamental reactions in organic chemistry, the Diels–Alder reaction between a conjugated diene and dienophile is widely applied to construct a six-membered carbo/hetero-cyclic ring.<sup>16,17</sup> By retrosynthetic analysis of *cis*-hydroindole, this chiral motif can be readily assembled from an electron-deficient diene and electron-rich cyclic enamine<sup>18</sup> *via* an enantioselective inverse-electron-demand Diels–Alder (IEDDA) reaction (Scheme 1b). Simultaneously, multiple stereocenters and dense functionalities can also be conveniently introduced into the resulting *cis*-hydroindole scaffolds in a single-step, which could be used for further functional group transformations and natural product synthesis. Due to the hemi-aromatic and adjustable electronic properties, electron-deficient 2-pyrone has become a favored diene component in the IEDDA reaction with a wide range of applications in aromatic compounds and complex natural product synthesis.<sup>19,20</sup> Particularly, the Cai group demonstrated the enantioselective IEDDA reaction of 3-carboalkoxyl-2-pyrone with electron-rich dienophiles, such as 2,2-dimethyl-1,3-dioxole,<sup>20g</sup> silyl cyclohexadienol<sup>20i</sup> and 1-naphthyl acetylenes,<sup>20j</sup> affording the products in high yield, excellent ee, and high dr. In spite of the above achievements, catalytic asymmetric synthesis of *cis*-hydroindoles *via* the enantioselective IEDDA reaction of 2-pyrones with cyclic enamines is still in its infancy so far. Recently, Jiang and co-workers disclosed an elegant diastereoselective IEDDA reaction of electron-deficient 2-pyrones with chiral cyclic enamines, affording the bridged *cis*-hydroindole derivatives in high yield with a moderate *exo/endo* ratio (Scheme 1c).<sup>21</sup> Herein, we describe our efforts towards an enantioselective IEDDA reaction catalyzed by the chiral *N,N'*-dioxide/Mg(OTf)<sub>2</sub> complex<sup>22</sup> using 3-carboalkoxyl-2-pyrone **1** and cyclic enamine **2** as the reaction partners (Scheme 1d). This reaction provided a facile and rapid route to access the bridged *cis*-hydroindole motif bearing four contiguous stereocenters with excellent levels of diastereo- and enantioselectivity. Furthermore, a formal total synthesis of bioactive (+)-minovincine alkaloid was furnished concisely and enantioselectively by subsequent transformation of the enantiomerically enriched products.

## Results and discussion

Our studies commenced by using 3-carbomethoxy-2-pyrone **1a** and cyclic enamine **2a** as model substrates to optimize the reaction conditions (Table 1). First of all, different metal salts coordinated with the *N,N'*-dioxide ligand **L<sub>3</sub>-PiPr<sub>2</sub>** were evaluated in DCE at 35 °C (entries 1–4). The results showed that Sc(OTf)<sub>3</sub> and In(OTf)<sub>3</sub> only led to trace yield of product **3a**, while Yb(OTf)<sub>3</sub> gave **3a** in 92% yield but 13% ee. To our delight, in the presence of the Mg(OTf)<sub>2</sub>/**L<sub>3</sub>-PiPr<sub>2</sub>** complex, the reaction occurred smoothly to generate the desired product **3a** in 73% yield with 78% ee (entry 4). Encouraged by these results, various chiral *N,N'*-dioxide ligands were investigated in cooperation with Mg(OTf)<sub>2</sub>, including changes in the length of the linker,

Table 1 Optimization of the reaction conditions<sup>a</sup>




Entry	Lewis acid	Ligand	<i>t</i> (h)	Yield <sup>b</sup> (%)	ee <sup>c</sup> (%)
1	Sc(OTf) <sub>3</sub>	<b>L<sub>3</sub>-PiPr<sub>2</sub></b>	24	Trace	—
2	In(OTf) <sub>3</sub>	<b>L<sub>3</sub>-PiPr<sub>2</sub></b>	24	Trace	—
3	Yb(OTf) <sub>3</sub>	<b>L<sub>3</sub>-PiPr<sub>2</sub></b>	3	92	13
4	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiPr<sub>2</sub></b>	3	73	78
5	Mg(OTf) <sub>2</sub>	<b>L<sub>2</sub>-PiPr<sub>2</sub></b>	12	99	68
6	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PrPr<sub>2</sub></b>	12	97	69
7	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-RaPr<sub>2</sub></b>	12	99	79
8	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiAd</b>	17	91	12
9	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiEt<sub>2</sub></b>	6	95	82
10	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiMe<sub>2</sub></b>	3	97	88
11 <sup>d</sup>	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiMe<sub>2</sub></b>	3	99	95
12 <sup>e</sup>	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiMe<sub>2</sub></b>	3	99	95
13 <sup>f</sup>	Mg(OTf) <sub>2</sub>	<b>L<sub>3</sub>-PiMe<sub>2</sub></b>	12	99	93

<sup>a</sup> Unless otherwise noted, all reactions were carried out with **1a** (0.10 mmol), **2a** (0.15 mmol), Lewis acid/ligand (1 : 1, 10 mol%) in DCE (0.5 mL) at 35 °C. <sup>b</sup> NMR yield detected by using CH<sub>2</sub>Br<sub>2</sub> as an internal standard. <sup>c</sup> Enantiomeric excess determined by HPLC analysis on a chiral stationary phase. <sup>d</sup> Carried out in CHCl<sub>3</sub> (0.5 mL). <sup>e</sup> Mg(OTf)<sub>2</sub>/**L<sub>3</sub>-PiMe<sub>2</sub>** (1 : 1, 5 mol%). <sup>f</sup> Mg(OTf)<sub>2</sub>/**L<sub>3</sub>-PiMe<sub>2</sub>** (1 : 1, 2 mol%). DCE = 1,2-dichloroethane, Tf = trifluoromethanesulfonyl.


backbones of chiral amino acids, and substituents on the aromatic amide group (entries 5–10). It was found that **L<sub>3</sub>-PiMe<sub>2</sub>** derived from 2,6-dimethyl aniline could improve the result dramatically, providing the product **3a** in 97% yield with 88% ee (entry 10). The screening of other solvents suggested that CHCl<sub>3</sub> could further increase the enantioselectivity to 95% ee (entry 11). Notably, when the catalyst loading was reduced to 5 mol%, there was no obvious effect on the outcomes (entry 12). A further decrease to 2 mol% still demonstrated excellent reactivity and a slight deterioration of the enantioselectivity (99% yield with 93% ee, entry 13).

After the optimal reaction conditions were established, the substrate scope of this transformation was further investigated (Table 2 and 3). It was found that 2-pyrones bearing various ester groups such as methyl, ethyl, isopropyl, allyl and benzyl groups were well tolerated, affording **3a–3e** in good yields with excellent enantioselectivities (60–99% yields and 86–95% ee). Meanwhile, the absolute configuration of product **3a** was determined unambiguously by X-ray crystallography analysis. 2-Pyrone with a methyl group at the C4 or C6 position was also compatible, providing **3f** and **3g** in excellent yields (90% and 86% yields) and ee values (89% and 94% ee). Unfortunately, when 2-pyrone contained a phenyl group at the C6 position, the IEDDA reaction did not occur, probably due to the steric effect.



**Table 2** Substrate scope of substituted 2-pyrones and cyclic enamines<sup>a</sup>

<sup>a</sup> All reactions were carried out with **1** (0.10 mmol), **2** (0.15 mmol), Mg(OTf)<sub>2</sub>/L<sub>3</sub>-PiMe<sub>2</sub> (1 : 1, 5 mol%) in CHCl<sub>3</sub> (0.5 mL) at 35 °C. Isolated yield. Enantiomeric excess was determined by HPLC on a chiral stationary phase. <sup>b</sup> Mg(OTf)<sub>2</sub>/L<sub>3</sub>-PiMe<sub>2</sub> (1 : 1, 10 mol%) was used.

**Table 3** Substrate scope of substituted 2-pyrones and acyclic enamines<sup>a</sup>


<sup>a</sup> All reactions were carried out with **1** (0.10 mmol), **2** (0.15 mmol), Mg(OTf)<sub>2</sub>/L<sub>3</sub>-PiMe<sub>2</sub> (1 : 1, 10 mol%) in CHCl<sub>3</sub> (0.5 mL) at 35 °C. Isolated yield. Enantiomeric excess was determined by HPLC on a chiral stationary phase. <sup>b</sup> The reaction was conducted at 35 °C for 36 h, and then heated at 110 °C for 2 h.

Next, the scope with respect to the substituted cyclic enamines was also examined. By changing different *N*-protecting groups of enamines, both Boc- and acetyl-protected cyclic enamines were confirmed to be well tolerated, affording **3i** and **3j** in good yields (80% and 92%) with high enantioselectivities (94% and 87% ee). The spiro-cyclic enamine **2k** was reactive as well to give desired product **3k** with moderate enantioselectivity. In addition, the chiral enamines **2l** and **2m** underwent the diastereoselective IEDDA reaction very well, delivering an exclusive diastereoisomer

**3l** and **3m**, respectively. Furthermore, the scope of acyclic enamines was also evaluated. As summarized in Table 3, terminal enamine **2n** reacted smoothly with 2-pyrone **1a** to afford the corresponding chiral bridged cyclolactone **3n** in 80% yield with 92% ee. C4- or C6-methyl substituted 2-pyrones were also tolerated (**3o** and **3p**), while cyclohexadiene **3p** was obtained in one pot through the tandem Diels–Alder reaction and *in situ* retro-[4 + 2] extrusion of CO<sub>2</sub> at an elevated temperature. We found that the methyl and benzyloxy substituted (*E*)-enamines **2q** and **2r** afforded the desired products in moderate to good yields and enantioselectivities. Gratifyingly, the IEDDA reaction of 2,3-dihydrofuran and 2-pyrone also occurred smoothly to provide **3s** in good yield but with a moderate ee (94% yield with 70% ee).

To illustrate the potential utility of the methodology, a scale-up synthesis of **3a** proceeded under the standard conditions. As shown in Scheme 2a, 2 mmol of compound **1a** reacted smoothly with 3 mmol of **2a**, furnishing the desired product **3a** in 82% yield with 96% ee after recrystallization. Meanwhile, several postcatalytic derivatizations were also conducted using enantiomerically pure product **3a**. By treatment with diazomethane and a catalytic amount of palladium acetate, the stereospecific cyclopropanation of the alkene motif in **3a** was accomplished, thus generating a complex polycyclic product **3t** in 68% yield with 96% ee and >20 : 1 dr. Complete extrusion of CO<sub>2</sub> *via* retro-Diels–Alder reaction led to the formation of a *cis*-tetrahydroindole structure **3u** without epimerization in chlorobenzene under reflux. Subsequent regioselective and stereoselective 1,6-Michael addition with MeLi and CuI afforded the corresponding *cis*-hexahydroindole derivative **3v** bearing multiple stereocenters in moderate yield with maintained enantioselectivity.

Natural product minovincine,<sup>23</sup> characterized by a spiroindoline pentacyclic framework with contiguous stereocenters, is considered as a “biogenetic turntable” between the vindoline and kopsinine classes of isolates.<sup>24</sup> Intrigued by its fascinating structural features and potential biological activities, minovincine has long attracted considerable interest within the chemical synthesis community.<sup>25,26</sup> However, there are few examples in the literature for the enantioselective total synthesis of (–)-minovincine.<sup>27–29</sup> Based on our present approach and



**Scheme 2** (a) Scale-up synthesis; (b) further transformation of the product. <sup>a</sup> Yield and enantiomeric excess were determined after recrystallization.



interest in synthesis of natural alkaloids,<sup>30</sup> the *cis*-hydroindole scaffold present in minovincine inspired us to develop a concise synthetic route for the enantioselective formal total synthesis of the naturally occurring enantiomer (+)-minovincine. As shown in Scheme 3, the enantiomerically pure product **3a** was readily reduced to **4** in 92% yield with 97% ee by treatment with 5 mol% Crabtree's catalyst under a hydrogen atmosphere. The hydrolysis of the tricyclic lactone **4** was then accomplished by using KOH, followed by extrusion of CO<sub>2</sub> and methyl esterification by using TMSCH<sub>2</sub>N<sub>2</sub> to afford the *cis*-hydroindole derivative **5** in 91% overall yield. Protection of the hydroxyl of **5** with *tert*-butyldimethylsilyl chloride (TBSCl) furnished **6** in almost quantitative yield. Subsequent deprotection of the benzyloxycarbonyl (Cbz) group of **6** (H<sub>2</sub>, Pd/C, EtOH, rt) led to **7** in good yield. Further *N*-alkylation of **7** with 1,3-diiodopropane produced **8** in 52% yield, then **8** was treated with LDA and DMPU to generate **9** bearing a key tricyclic framework. Exposure of **9** to aq. HCl (1 M) gave the corresponding alcohol, which was further oxidized by PySO<sub>3</sub> to form the common-core structure **10** in 70% yield over two steps. The absolute configuration of **10** was determined to be opposite to that reported by Soós, and then it could be converted into (+)-minovincine in three steps according to a known procedure.<sup>29</sup>

Based on the crystal structures of chiral *N,N'*-dioxide-metal complexes<sup>22a</sup> and the absolute configuration of this IEDDA reaction product, we proposed a putative stereochemical model to rationalize the stereoselectivity shown in Fig. 1. The coordination of the chiral *N,N'*-dioxide ligand **L<sub>3</sub>-PiMe<sub>2</sub>** with Mg(OTf)<sub>2</sub> in a tetradentate manner generates an octahedral structure. Then 2-pyrone **1a** coordinates tightly to the Lewis acid catalyst through the two carbonyl groups of the ester motif, resulting in a decrease of its LUMO level to accelerate the IEDDA reaction. Simultaneously, due to the steric hindrance of the bulky amide group of the ligand, cyclic enamine **2a** prefers to attack from the *Si*-face of 2-pyrone to give *endo*-adduct (**3a**, 4*R*, 7*S*, 7*aS*)-**3a** with excellent stereoselectivity.

## Conclusions

In conclusion, we have developed a novel strategy for the highly enantioselective synthesis of the *cis*-hydroindole motif,




Fig. 1 Proposed stereochemical model.

involving a chiral *N,N'*-dioxide/Mg(OTf)<sub>2</sub> complex catalyzed asymmetric IEDDA reaction of 2-pyrones and cyclic enamines. A range of *cis*-hydroindole derivatives were obtained in good yields with high stereoselectivities under mild reaction conditions (up to 99% yield, and 95% ee). This protocol was also compatible for acyclic enamines and 2,3-dihydrofuran. Meanwhile, the scale-up synthesis and further postcatalytic derivatizations were conducted to measure the synthetic potential of the method. Particularly, an alternative and facile access to efficient formal total synthesis of (+)-minovincine was demonstrated by employing the transformations. Further investigations of this reaction in total synthesis of other bioactive natural products are ongoing in our laboratory.

## Data availability

All experimental and characterization data in this manuscript are available in the ESI†. Crystallographic data for compound (**3a**, 4*R*, 7*S*, 7*aS*)-**3a** has been deposited at the Cambridge Crystallographic Data Center and assigned number 2158164.

## Author contributions

F. Q. Z. performed the experiments and prepared the ESI† and paper. B. T. R. performed some experiments. Y. Q. Z. helped with resolving the X-ray crystallographic data. Y. B. L. and X. M. F. conceived the concept, directed the project and helped with modifying the paper and ESI†.

## Conflicts of interest


There are no conflicts to declare.

## Acknowledgements

We are grateful for the financial support from National Natural Science Foundation of China (No. 22001177) and Shenzhen Bay Laboratory (No. S201100003 and S211101001-1).

## Notes and references


- 1 M. E. Amer, M. Shamma and A. J. Freyer, *J. Nat. Prod.*, 1991, **54**, 329–363.
- 2 J. Leonard, *Nat. Prod. Rep.*, 1999, **16**, 319–338.



Scheme 3 Enantioselective formal total synthesis of (+)-minovincine. TBSCl = *tert*-butyldimethylsilyl chloride, LDA = lithium diisopropylamide, DMPU = 1,3-dimethyl-tetrahydropyrimidin-2(1*H*)-one.



- 3 S. E. O'Connor and J. J. Maresh, *Nat. Prod. Rep.*, 2006, **23**, 532–547.
- 4 K. Ersmark, J. R. Del Valle and S. Hanessian, *Angew. Chem., Int. Ed.*, 2008, **47**, 1202–1223.
- 5 R. A. Pilli, G. B. Rosso and M. d. C. F. de Oliveira, *Nat. Prod. Rep.*, 2010, **27**, 1908–1937.
- 6 J. Khazir, B. A. Mir, S. A. Mir and D. Cowan, *J. Asian Nat. Prod. Res.*, 2013, **15**, 764–788.
- 7 Y. Wang, F. Xie, B. Lin, M. Cheng and Y. Liu, *Chem.–Eur. J.*, 2018, **24**, 14302–14315.
- 8 J. M. Saya, E. Ruijter and R. V. A. Orru, *Chem.–Eur. J.*, 2019, **25**, 8916–8935.
- 9 M. Hurst and B. Jarvis, *Drugs*, 2001, **61**, 867–896.
- 10 F. J. Sayago, P. Laborda, M. I. Calaza, A. I. Jiménez and C. Cativiela, *Eur. J. Org. Chem.*, 2011, 2011–2028.
- 11 E. Arceo, I. D. Jurberg, A. Álvarez-Fernández and P. Melchiorre, *Nat. Chem.*, 2013, **5**, 750–756.
- 12 For chiral pool approaches, see: (a) P. Wipf, Y. Kim and D. M. Goldstein, *J. Am. Chem. Soc.*, 1995, **117**, 11106–11112; (b) J. Bonjoch, J. Catena, E. Isàbal, M. López-Canet and N. Valls, *Tetrahedron: Asymmetry*, 1996, **7**, 1899–1902; (c) S. Hanessian and M. Tremblay, *Org. Lett.*, 2004, **6**, 4683–4686; (d) B. M. Ruff, S. Zhong, M. Nieger, M. Sickert, C. Schneider and S. Bräse, *Eur. J. Org. Chem.*, 2011, 6558–6566; (e) S. Hanessian, S. Dorich and H. Menz, *Org. Lett.*, 2013, **15**, 4134–4137.
- 13 For asymmetric metal-catalyzed reactions, see: (a) C. S. Schindler, S. Diethelm and E. M. Carreira, *Angew. Chem., Int. Ed.*, 2009, **48**, 6296–6299; (b) B. M. Trost, T. Kaneko, N. G. Andersen, C. Tappertzhofen and B. Fahr, *J. Am. Chem. Soc.*, 2012, **134**, 18944–18947; (c) Z. Sun, M. Zhou, X. Li, X. Meng, F. Peng, H. Zhang and Z. Shao, *Chem.–Eur. J.*, 2014, **20**, 6112–6119; (d) D. Dailler, G. Danoun and O. Baudoin, *Angew. Chem., Int. Ed.*, 2015, **54**, 4919–4922.
- 14 For aminocatalysis, see: L. Pantaine, V. Coeffard, X. Moreau and C. Greck, *Org. Lett.*, 2015, **17**, 3674–3677.
- 15 For chiral Brønsted acid catalysts, see: (a) Y. Han, B. Zheng and Y. Peng, *Adv. Synth. Catal.*, 2015, **357**, 1136–1142; (b) C. Parra, C. Bosch, E. Gómez-Bengoa, J. Bonjoch and B. Bradshaw, *J. Org. Chem.*, 2016, **81**, 10172–10179.
- 16 For selected reviews, see: (a) H. B. Kagan and O. Riant, *Chem. Rev.*, 1992, **92**, 1007–1019; (b) J. D. Winkler, *Chem. Rev.*, 1996, **96**, 167–176; (c) E. J. Corey, *Angew. Chem., Int. Ed.*, 2002, **41**, 1650–1667; (d) K. C. Nicolaou, S. A. Snyder, T. Montagnon and G. Vassilikogiannakis, *Angew. Chem., Int. Ed.*, 2002, **41**, 1668–1698; (e) K.-i. Takao, R. Munakata and K.-i. Tadano, *Chem. Rev.*, 2005, **105**, 4779–4807; (f) J. Han, A. X. Jones and X. Lei, *Synthesis*, 2015, **47**, 1519–1533; (g) M. S. Xie, L. L. Lin and X. M. Feng, *Chem. Rec.*, 2017, **17**, 1184–1202.
- 17 For selected examples about the Diels–Alder reaction from our group, see: (a) M. S. Xie, X. H. Chen, Y. Zhu, B. Gao, L. L. Lin, X. H. Liu and X. M. Feng, *Angew. Chem., Int. Ed.*, 2010, **49**, 3799–3802; (b) H. P. Hu, Y. B. Liu, J. Guo, L. L. Lin, Y. L. Xu, X. H. Liu and X. M. Feng, *Chem. Commun.*, 2015, **51**, 3835–3837; (c) X. Y. Hao, L. L. Lin, F. Tan, C. K. Yin, X. H. Liu and X. M. Feng, *ACS Catal.*, 2015, **5**, 6052–6056; (d) H. F. Zheng, X. H. Liu, C. R. Xu, Y. Xia, L. L. Lin and X. M. Feng, *Angew. Chem., Int. Ed.*, 2015, **54**, 10958–10962; (e) Y. Lu, Y. H. Zhou, L. L. Lin, H. F. Zheng, K. Fu, X. H. Liu and X. M. Feng, *Chem. Commun.*, 2016, **52**, 8255–8258; (f) Y. H. Zhou, Y. Lu, X. Y. Hu, H. J. Mei, L. L. Lin, X. H. Liu and X. M. Feng, *Chem. Commun.*, 2017, **53**, 2060–2063.
- 18 For an important application of cyclic enamines, see: L. Bai, Y. Ma and X. Jiang, *J. Am. Chem. Soc.*, 2021, **143**, 20609–20615.
- 19 For selected reviews, see: (a) K. Afarinkia, V. Vinader, T. D. Nelson and G. H. Posner, *Tetrahedron*, 1992, **48**, 9111–9171; (b) X. Jiang and R. Wang, *Chem. Rev.*, 2013, **113**, 5515–5546; (c) Q. Cai, *Chin. J. Chem.*, 2019, **37**, 946–976; (d) X.-G. Si, Z.-M. Zhang and Q. Cai, *Synlett*, 2021, **32**, 947–954; (e) G. Huang, C. Kouklovsky and A. de la Torre, *Chem.–Eur. J.*, 2021, **27**, 4760–4788.
- 20 For selected examples, see: (a) G. H. Posner, J.-C. Carry, J. K. Lee, D. S. Bull and H. Dai, *Tetrahedron Lett.*, 1994, **35**, 1321–1324; (b) I. E. Markó, G. R. Evans and J.-P. Declercq, *Tetrahedron*, 1994, **50**, 4557–4574; (c) G. H. Posner, H. Dai, D. S. Bull, J.-K. Lee, F. Eydoux, Y. Ishihara, W. Welsh, N. Pryor and S. Petr, *J. Org. Chem.*, 1996, **61**, 671–676; (d) I. E. Markó, I. Chellé-Regnaut, B. Leroy and S. L. Warriner, *Tetrahedron Lett.*, 1997, **38**, 4269–4272; (e) Y. Hashimoto, R. Abe, N. Morita and O. Tamura, *Org. Biomol. Chem.*, 2018, **16**, 8913–8916; (f) Y. Zhou, Z. Zhou, W. Wu and Y. Chen, *Acta Chim. Sin.*, 2018, **76**, 382–386; (g) X.-W. Liang, Y. Zhao, X.-G. Si, M.-M. Xu, J.-H. Tan, Z.-M. Zhang, C.-G. Zheng, C. Zheng and Q. Cai, *Angew. Chem., Int. Ed.*, 2019, **58**, 14562–14567; (h) C. J. F. Cole, L. Fuentes and S. A. Snyder, *Chem. Sci.*, 2020, **11**, 2175–2180; (i) X.-G. Si, Z.-M. Zhang, C.-G. Zheng, Z.-T. Li and Q. Cai, *Angew. Chem., Int. Ed.*, 2020, **59**, 18412–18417; (j) M.-M. Xu, X.-Y. You, Y.-Z. Zhang, Y. Lu, K. Tan, L. Yang and Q. Cai, *J. Am. Chem. Soc.*, 2021, **143**, 8993–9001; (k) M.-M. Xu, L. Yang, K. Tan, X. Chen, Q.-T. Lu, K. N. Houk and Q. Cai, *Nat. Catal.*, 2021, **4**, 892–900; (l) Y. Lu, M.-M. Xu, Z.-M. Zhang, J. Zhang and Q. Cai, *Angew. Chem., Int. Ed.*, 2021, **60**, 26610–26615.
- 21 (a) M. Feng and X. Jiang, *Chem. Commun.*, 2014, **50**, 9690–9692; (b) N. Wang, S. Du, D. Li and X. Jiang, *Org. Lett.*, 2017, **19**, 3167–3170; (c) N. Wang, J. Liu, C. Wang, L. Bai and X. Jiang, *Org. Lett.*, 2018, **20**, 292–295.
- 22 For selected reviews about the properties of chiral *N,N'*-dioxide–Lewis acid complexes, see: (a) X. H. Liu, L. L. Lin and X. M. Feng, *Acc. Chem. Res.*, 2011, **44**, 574–587; (b) X. H. Liu, L. L. Lin and X. M. Feng, *Org. Chem. Front.*, 2014, **1**, 298–302; (c) X. H. Liu, H. F. Zheng, Y. Xia, L. L. Lin and X. M. Feng, *Acc. Chem. Res.*, 2017, **50**, 2621–2631; (d) X. H. Liu, S. X. Dong, L. L. Lin and X. M. Feng, *Chin. J. Chem.*, 2018, **36**, 791–797; (e) M. Y. Wang and W. Li, *Chin. J. Chem.*, 2021, **39**, 969–984; (f) S. X. Dong, X. H. Liu and X. M. Feng, *Acc. Chem. Res.*, 2022, **55**, 415–428.
- 23 For isolation of minovincine, see: (a) M. Plat, J. LeMen, M.-M. Janot, H. Budzikiewicz, J. M. Wilson, L. J. Durham and C. Djerassi, *Bull. Chem. Soc. Chim. Fr.*, 1962, 2237–



- 2241; (b) M. P. Cava, S. S. Tjoa, Q. A. Ahmed and A. I. Da Rocha, *J. Org. Chem.*, 1968, **33**, 1055–1059.
- 24 W. Zi, Z. Zuo and D. Ma, *Acc. Chem. Res.*, 2015, **48**, 702–711.
- 25 For a racemic total synthesis, see: (a) M. E. Kuehne and W. G. Earley, *Tetrahedron*, 1983, **39**, 3707–3714; (b) M. E. Kuehne and W. G. Earley, *Tetrahedron*, 1983, **39**, 3715–3717; (c) G. Kalaus, I. Juhász, I. Greiner, M. Kajtár-Peredy, J. Brlik, L. Szabó and C. Szántay, *J. Org. Chem.*, 1997, **62**, 9188–9191; (d) G. Kalaus, L. Léder, I. Greiner, M. Kajtár-Peredy, K. Vékey, L. Szabó and C. Szántay, *Tetrahedron*, 2003, **59**, 5661–5666.
- 26 For a semisynthesis, see: N. Langlois and R. Z. Andriamialisoa, *J. Org. Chem.*, 1979, **44**, 2468–2471.
- 27 B. N. Laforteza, M. Pickworth and D. W. C. MacMillan, *Angew. Chem., Int. Ed.*, 2013, **52**, 11269–11272.
- 28 T. Morikawa, S. Harada and A. Nishida, *J. Org. Chem.*, 2015, **80**, 8859–8867.
- 29 S. Varga, P. Angyal, G. Martin, O. Egyed, T. Holczbauer and T. Soós, *Angew. Chem., Int. Ed.*, 2020, **59**, 13547–13551.
- 30 (a) J. Xu, Z. W. Zhong, M. Y. Jiang, Y. Q. Zhou, X. H. Liu and X. M. Feng, *CCS Chem.*, 2021, **3**, 1894–1902; (b) J. Xu, R. Z. Li, N. Xu, X. H. Liu, F. Wang and X. M. Feng, *Org. Lett.*, 2021, **23**, 1856–1861.

